Phaseline

Targets › GUCY1A2

GUCY1A2 (Guanylate cyclase soluble subunit alpha-2): drug programs, companies and trials

11 programs from 11 companies in 23 trials: 9 Phase 2, 6 Phase 4, 5 Phase 3, 3 Phase 1; Cardiovascular, Oncology, Genitourinary; next expected readout Jun 2027.

Alpha subunit of soluble guanylate cyclase (sGC), a central enzyme in nitric oxide (NO) signaling. Functions as the main intracellular receptor for NO. Upon NO binding, catalyzes the conversion of GTP to cyclic GMP (cGMP) and thereby transducing NO signal into a ubiquitous intracellular second messenger..; FUNCTION: [Isoform 2]: Acts as a negative regulator of guanylyl cyclase activity as it forms non-functional…. (UniProt, P33402)

Open in Phaseline: the race on GUCY1A2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Cheng-Kung University HospitalNitroglycerin
Soluble guanylate cyclase activator
GUCY1B1, GUCY1A2, GUCY1A1Phase 4PancreatitisJul 2027
Children's Hospital Medical Center, CincinnatiNitric Oxide
Soluble guanylate cyclase activator
GUCY1B1, GUCY1A2, GUCY1A1Phase 3AKIJun 2027
Xijing HospitalNitric Oxide
Soluble guanylate cyclase activator
GUCY1B1, GUCY1A2, GUCY1A1Phase 3Nitric OxideMar 2028
BayerRiociguat
Soluble guanylate cyclase positive allosteric modulator
GUCY1B1, GUCY1A2, GUCY1A1Phase 3Hypertension, Pulmonary; Chronic Thromboembolic Pulmonary Hypertension; Pulmonary Arterial HypertensionMay 2028
Akebia TherapeuticsPraliciguat
Soluble guanylate cyclase activator
GUCY1B1, GUCY1A2, GUCY1A1Phase 2Focal Segmental GlomerulosclerosisJun 2027
KardiganAtaciguat
Soluble guanylate cyclase activator
GUCY1B1, GUCY1A2, GUCY1A1Phase 2Moderate Aortic Valve StenosisAug 2028
Merck & Co. (MSD)Vericiguat
Soluble guanylate cyclase activator
GUCY1B1, GUCY1A2, GUCY1A1Phase 2Heart Failure; Heart Failure With Reduced Ejection Fraction (HFrEF); Endothelial Dysfunction; Post-COVID ME/CFS …Aug 2029
Steven MesseNitric Oxide
Soluble guanylate cyclase activator
GUCY1B1, GUCY1A2, GUCY1A1Phase 2Stroke–
Beni-Suef UniversityNitroglycerin
Soluble guanylate cyclase activator
GUCY1B1, GUCY1A2, GUCY1A1Phase 2COPD–
Mayo ClinicIsosorbide Mononitrate
Soluble guanylate cyclase activator
GUCY1B1, GUCY1A2, GUCY1A1Phase 1Malignant Digestive System NeoplasmApr 2028
Vanderbilt UniversityNitroglycerin
Soluble guanylate cyclase activator
GUCY1B1, GUCY1A2, GUCY1A1Phase 1HypertensionJul 2028

Conditions

Heart Failure (3) Chronic Thromboembolic Pulmonary Hypertension (2) Pulmonary Arterial Hypertension (2) Nitric Oxide (1) COPD (1) Heart Failure With Reduced Ejection Fraction (HFrEF) (1) Endothelial Dysfunction (1) Post-COVID ME/CFS (1) Breast Cancer (1) Calcific Aortic Valve Disease (1) Decompensated Heart Failure (1) Pancreatitis (1)

Modalities

small molecule (11)

Companies

Xijing Hospital (1) Beni-Suef University (1) Merck & Co. (MSD) (1) National Cheng-Kung University Hospital (1) Children's Hospital Medical Center, Cincinnati (1) Kardigan (1) Bayer (1) Akebia Therapeutics (1) Vanderbilt University (1) Mayo Clinic (1) Steven Messe (1)

Related targets

GUCY1B1 (11) GUCY1A1 (11)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.